Bristol-Myers Squibb announces results of BMS-708163 Stage II study on Alzheimer’s Bristol-Myers Squibb Firm today announced the results of a Stage II research evaluating the basic safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in individuals with mild-to-moderate Alzheimer’s disease. The randomized, double-blind, placebo-controlled research demonstrated that BMS-708163 dosages below 100 mg/day provide a potential therapeutic home window for further evaluation in Phase III registrational studies. The study outcomes were provided at the 2011 Alzheimer’s Association International Meeting here . Of the four BMS-708163 dosages evaluated in the study , dosages below 100 mg/time demonstrated acceptable tolerability profiles for further advancement and were associated with discontinuation rates comparable with placebo.

She was my greatest friend and if I have attained anything in this full life, for the reason that of her. This race is about the patients we serve, their own families, their doctors and their nurses who fight each day for them, stated E. G. Bubba Klugh, Bristol-Myers Squibb, Small Rock, AR. Working out before our trip has been strenuous, however the discipline required is part of what makes Coast 2 Coast 4 Cancer so meaningful to the riders because we are riding for individuals. We’d all ride as far as it requires – for them.


Other Posts From Category "tempered":

Related Posts